Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 83 Breast Neoplasms 60 Prostatic Neoplasms 30 Triple Negative Breast Neoplasms 26 Neoplasms 24 Fallopian Tube Neoplasms 22 Neoplasm Metastasis 18 Pancreatic Neoplasms 17 Endometrial Neoplasms 17 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 10 Sarcoma 9 Carcinoma, Non-Small-Cell Lung 9 Stomach Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Lung Neoplasms 7 Glioma 7 Fanconi Anemia, Complementation Group D1 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Glioblastoma 6 Colorectal Neoplasms 6 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Solid Tumors 4 Neuroendocrine Tumors 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Squamous Cell 4 Advanced Solid Tumors 4

Interventions

Cisplatin 121 Gemcitabine 67 Radiotherapy, Intensity-Modulated 58 Docetaxel 36 toripalimab 34 Fluorouracil 34 Capecitabine 34 Radiotherapy 21 Drug Therapy 20 camrelizumab 19 nimotuzumab 18 spartalizumab 12 pembrolizumab 12 nedaplatin 12 apatinib 11 Induction Chemotherapy 11 sintilimab 10 Chemoradiotherapy 10 tislelizumab 9 Magnetic Resonance Spectroscopy 9 Carboplatin 9 Specimen Handling 8 Radiation 8 Nivolumab 8 Cetuximab 8 Bevacizumab 8 endostar protein 7 Paclitaxel 7 Immune Checkpoint Inhibitors 7 Endostatins 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04825990 2022-04-07

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡